Prognostic Stage IV Breast Cancer AJCC v8 Recruiting Phase 1 / 2 Trials for Fulvestrant (DB00947)

IndicationStatusPhase
DBCOND0109667 (Prognostic Stage IV Breast Cancer AJCC v8)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05319873Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerTreatment